Can-Fite BioPharma Ltd.

Contributing Author

Recent Articles by Can-Fite BioPharma Ltd.

Nov-26	Can-Fite's Latest Developments of its Advanced Stage Drug Pipeline will be Presented at Noble Capital Markets 21st Annual Emerging Growth Equity Conference CANF GlobeNewswire
Nov-24	Can-Fite to Advance New Veterinary Partnership Opportunities for Namodenoson at the BioFIT 2025 Conference CANF GlobeNewswire
Nov-20	Can-Fite's CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil CANF GlobeNewswire
Nov-18	Can-Fite: 9-Year Survival with Complete Cure in an Advanced Liver Cancer Patient Treated with Namodenoson CANF GlobeNewswire
Sep-15	Can-Fite Reports Complete Resolution of Esophageal Varices in Decompensated Cirrhosis Patient Treated with Namodenoson CANF GlobeNewswire
Aug-28	Can-Fite Reports H1 2025 Financial Results and Clinical Update CANF GlobeNewswire
Jul-30	Pancreatic Cancer Phase 2a Study with Can-Fite's Namodenoson Achieved Over 50% Enrollment Milestone CANF GlobeNewswire
Jul-28	Can-Fite Announces Up To $15.0 Million Public Offering CANF GlobeNewswire
Jul-28	Breakthrough Study from UCLA Demonstrate Can-Fite's Piclidenoson as a Treatment for Vascular Dementia CANF GlobeNewswire
Jun-16	Can-Fite to Present Phase IIa Pancreatic Cancer Study Progress During Partnering Meetings at the 2025 BIO International Convention in Boston CANF GlobeNewswire
May-05	Can-Fite Has Raised $175 Million in Total to Date for the Development of Namodenoson and Piclidenoson, Advancing into Pivotal Phase 3 Trials in Liver Cancer and Psoriasis CANF GlobeNewswire